## **Core Concept**
The question targets knowledge about disease-modifying therapies (DMTs) in multiple sclerosis (MS), specifically their impact on the Expanded Disability Status Scale (EDSS). EDSS is a method of quantifying disability in MS. The correct answer should be a drug known to have a beneficial effect on EDSS scores.

## **Why the Correct Answer is Right**
The correct answer, , is recognized for its efficacy in reducing the relapse rate and slowing the progression of disability in MS patients, as measured by EDSS. It works by depleting CD20+ B cells, which play a role in the pathogenesis of MS. Clinical trials have demonstrated that can lead to improvements in EDSS scores, making it a valuable treatment option for MS patients.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is not primarily known for improving EDSS scores in MS. It has other therapeutic applications.
- **Option B:** has some effect on MS symptoms but is not specifically noted for improving EDSS scores like the correct answer.
- **Option D:** may have some benefits in MS management but is not highlighted for its effect on EDSS scores.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that is a monoclonal antibody targeting CD20+ B cells and has shown significant benefits in MS management, including effects on EDSS scores. This makes a critical drug in the treatment arsenal for MS.

## **Correct Answer:** .